NTLA
What one share of Intellia Therapeutics holds
In Vitro and In Vivo Diagnostic Substances
Intellia Therapeutics, Inc. (“we,” “us,” “our,” “Intellia,” or the “Company”) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. Our mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments.
Intellia Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.50 |
|---|---|
| Profit | −$3.34 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$2.92 |
| Cash and investments | $4.49 |
| Book value | $5.20 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.74 | −$1.42 | $0.28 | $1.35 | — | $5.83 |
| 2017 | $0.73 | −$1.88 | $0.28 | −$2.09 | — | $7.09 |
| 2018 | $0.71 | −$1.98 | $0.15 | −$1.57 | — | $6.15 |
| 2020 | $1.04 | −$2.40 | $0.06 | −$0.96 | — | $7.96 |
| 2021 | $0.47 | −$3.78 | $0.18 | −$3.35 | — | $13.97 |
| 2022 | $0.68 | −$6.16 | $0.18 | −$4.51 | — | $14.19 |
| 2023 | $0.41 | −$5.42 | $0.16 | −$4.60 | — | $11.29 |
| 2024 | $0.59 | −$5.25 | $0.06 | −$3.59 | — | $8.55 |
| 2025 | $0.62 | −$3.81 | $0.01 | −$3.65 | — | $5.77 |